4th Quarter - Report

BIOTECHNOLOGY INNOVATION ORGANIZATION for BIOTECHNOLOGY INNOVATION ORGANIZATION

Firm
Client
Income
—
Expenses
$2,110,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

17 issue areas, each in the filer's own words, with who lobbied on it and where.

Chemicals/Chemical Industry CHM

Renewable Chemicals/Bio-based Products (Non-Funding) ---Nomenclature Usage ---Pre-market Notification Review ---S. 697: Chemical Safety for the 21st Century Act ---H.R. 2576: TSCA Modernization Act ---S. 1447: Sustainable Chemistry Research and Development Act ---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act Funding for Renewable Chemicals/Bio-based Products ---H.R.2029: Consolidated Appropriations Act for FY 2016

LobbyistCovered position, as disclosed
TOM DILENGE —
CHARLES H FRITTS —
JEANNE HAGGERTY —
TRACEY LATURNER —
ERICK LUTT —
RINA SINGH —

Contacted: Environmental Protection Agency (EPA); Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); SENATE; Office of the Vice President of the United States; Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Securities & Exchange Commission (SEC); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Agriculture, Dept of (USDA); Natl Security Council (NSC); Office of Management & Budget (OMB); Patent & Trademark Office (PTO)

Bills named: H.R. 3084 (114th), S. 1267 (114th), S. 697 (114th), H.R. 2576 (114th), S. 1447 (114th), H.R. 2029 (114th)

Science/Technology SCI

Synthetic Biology Issue ---H.R. 591: Engineering Biology Research and Development Act

LobbyistCovered position, as disclosed
TOM DILENGE —
JEANNE HAGGERTY —
DANA MAURICE O'BRIEN —
RINA SINGH —

Contacted: Centers For Medicare and Medicaid Services (CMS); Securities & Exchange Commission (SEC); Office of Science & Technology Policy (OSTP); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Patent & Trademark Office (PTO); Agriculture, Dept of (USDA); U.S. Trade Representative (USTR); Environmental Protection Agency (EPA); Natl Security Council (NSC); Office of Management & Budget (OMB); Congressional Budget Office (CBO); SENATE; Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES

Bills named: H.R. 591 (114th)

Animals ANI

Livestock Cloning/Product Labeling ---Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals ---FDA Approval ---Labeling ---One Health Legislation (Senate Discussion Draft) ---H.R.2029: Consolidated Appropriations Act for FY 2016 -------Amendment to Restrict FDA Approval of GE Salmon -------Amendment on GE Salmon Labeling

LobbyistCovered position, as disclosed
BRIAN T BAENIG —
JEANNE HAGGERTY —
TRACEY LATURNER —
DANA MAURICE O'BRIEN —
MATTHEW O'MARA —

Contacted: Health Resources & Services Administration (HRSA); SENATE; Agriculture, Dept of (USDA); Centers For Medicare and Medicaid Services (CMS); Office of the Vice President of the United States; Natl Institutes of Health (NIH); Natl Security Council (NSC); Environmental Protection Agency (EPA); Office of Management & Budget (OMB); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Congressional Budget Office (CBO); Securities & Exchange Commission (SEC); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP)

Bills named: H.R. 2029 (114th)

Fuel/Gas/Oil FUE

Biofuels (Non-Funding) ---Accelerated Depreciation Extension ---Climate Change Benefits ---Production Tax Credit Extension ---Implementation of the Agricultural Act of 2014 ---H.R. 2029: Consolidated Appropriations Act of FY 2016 -------Protecting Americans from Tax Hikes (PATH) Act of 2015 Renewable Chemicals/Bio-based Products (Non-Funding) ---Nomenclature Usage ---Pre-market Notification Review ---S. 697: Chemical Safety for the 21st Century Act ---H.R. 2576: TSCA Modernization Act ---S. 1447: Sustainable Chemistry Research and Development Act ---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act Funding for Biomass Crop Assistance Program ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Renewable Chemicals/Bio-based Products ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biofuels ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biorefineries --H.R.2029: Consolidated Appropriations Act for FY 2016 EPA Regulation of Biotechnology ---EPA Points to Consider Guidance Document for GE Algae Renewable Fuel Standard ---Proposed Rule Review of the Federal Coordinated Framework for Biotechnology Products

LobbyistCovered position, as disclosed
TOM DILENGE —
CHARLES H FRITTS —
JEANNE HAGGERTY —
TRACEY LATURNER —
ERICK LUTT —
RINA SINGH —

Contacted: Office of the Vice President of the United States; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Natl Security Council (NSC); SENATE; Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Office of Science & Technology Policy (OSTP); Agriculture, Dept of (USDA); HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); Securities & Exchange Commission (SEC)

Bills named: S. 697 (114th), H.R. 3084 (114th), H.R. 2029 (114th), S. 1267 (114th), H.R. 2576 (114th), S. 1447 (114th)

Homeland Security HOM

Biodefense Research, Development, and Procurement Issues (Non-funding) Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.R.2029: Consolidated Appropriations Act for FY 2016

LobbyistCovered position, as disclosed
PHYLLIS ARTHUR —
KELLY CAPPIO —
JAMIE GREGORIAN —
JEANNE HAGGERTY —
TRACEY LATURNER —
NICK MAGALLANES —
AMY WALKER —

Contacted: Agriculture, Dept of (USDA); Securities & Exchange Commission (SEC); Office of the Vice President of the United States; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Environmental Protection Agency (EPA); Natl Security Council (NSC); Patent & Trademark Office (PTO); Office of Management & Budget (OMB); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO)

Bills named: H.R. 2029 (114th)

Trade (domestic/foreign) TRD

Drug Importation ---H.R.2029: Consolidated Appropriations Act for FY 2016 ---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015 Intellectual Property International Enforcement Foreign Agricultural Biotechnology Laws and Regulations ---Korea Biotechnology Regulations ---Asynchrony of International Approvals ---EU Ag Biotech Policies and Regulations ---China Biotechnology Regulations Biosimilars ---Mexico Biologics Regulations ---Colombia Biologics Regulations TransPacific Partnership ---Sanitary and Phytosanitary Issues ---Data and Intellectual Property Protections for Pharmaceuticals Transatlantic Trade and Investment Partnership ---Intellectual Property Issues ---Reimbursement Transparency

Contacted: Natl Security Council (NSC); Natl Institutes of Health (NIH); Office of Management & Budget (OMB); Congressional Budget Office (CBO); Agriculture, Dept of (USDA); Patent & Trademark Office (PTO); Securities & Exchange Commission (SEC); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; SENATE; Office of the Vice President of the United States

Bills named: H.R. 2029 (114th)

Agriculture AGR

EPA Regulations on Agricultural Biotechnology ---Pesticide Registration Improvement Act Livestock Cloning/Product Labeling ---Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals ---FDA Approval ---Labeling ---One Health Legislation (Senate Discussion Draft) ---H.R.2029: Consolidated Appropriations Act for FY 2016 -------Amendment to Restrict FDA Approval of GE Salmon -------Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology ---U.S. Government Policy ---H.R. 1599: Safe and Accurate Food Labeling Act of 2015 ---H.R.2029: Consolidated Appropriations Act for FY 2016 Transpacific Partnership ---Sanitary and Phytosanitary Issues Adventitious Presence (Low Level Presence) ---International Low Level Presence Policies Funding for the USDA ---H.R.2029: Consolidated Appropriations Act for FY 2016 Foreign Agricultural Biotechnology Laws and Regulations ---Asynchrony of International Approvals ---China Biotechnology Regulations ---EU Ag-Biotech Policies and Regulations ---Korea Biotechnology Regulations Potential Regulation of New Genetic Modification Technologies Funding for Biomass Crop Assistance Program ---H.R.2029: Consolidated Appropriations Act for FY 2016 USDA/APHIS Agricultural Biotechnology Regulations ---Efficient Science-Based Review of Biotech Products ---Co-existence of Production Systems Review of the Federal Coordinated Framework for Biotechnology Products

LobbyistCovered position, as disclosed
BRIAN T BAENIG —
TOM DILENGE —
JEANNE HAGGERTY —
TRACEY LATURNER —
DANA MAURICE O'BRIEN —
MATTHEW O'MARA —

Contacted: Agriculture, Dept of (USDA); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Environmental Protection Agency (EPA); Office of Management & Budget (OMB); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Securities & Exchange Commission (SEC); Natl Security Council (NSC); Patent & Trademark Office (PTO); SENATE; Office of Science & Technology Policy (OSTP); Office of the Vice President of the United States

Bills named: H.R. 2029 (114th), H.R. 1599 (114th)

Taxation/Internal Revenue Code TAX

Renewable Chemicals/Bio-based Products ---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act Biofuels (Non-Funding) ---Accelerated Depreciation Extension ---Production Tax Credit Extension ---H.R.2029: Consolidated Appropriations Act for FY 2016 ------Protecting Americans from Tax Hikes (PATH) Act of 2015 Research & Development Tax Credit Reforms ---Extension ---Permanency ---Refundable R&D Credit ---H.R.880: To amend the Internal Revenue Code to make permanent the credit for increasing research activities ---S. 537: COMPETE Act ---S. 341: Start-up Jobs and Innovation Act ---H.R.2029: Consolidated Appropriations Act for FY 2016 ------Protecting Americans from Tax Hikes (PATH) Act of 2015 Antibiotic & Diagnostic Tax Credit ---H.R. 3539: Antibiotic & Diagnostic Innovation Act Capital Formation Investment Incentives ---Reform of Capital Gains Rules ---Reform of Net Operating Loss Rules ---Reform of Passive Loss Rules ---S. 537: COMPETE Act ---S. 341: Start-up Jobs and Innovation Act ---H.R. 2179: PARTNER Act Tax Reform ---Innovation Box/Patent Box Orphan Drug Act Tax Credit Controlled Foreign Corporation Look-Through Rule Extension ---H.R.2029: Consolidated Appropriations Act for FY 2016 ------Protecting Americans from Tax Hikes (PATH) Act of 2015 Inversions ---H.R.2029: Consolidated Appropriations Act for FY 2016

Contacted: Natl Institutes of Health (NIH); Office of Science & Technology Policy (OSTP); Agriculture, Dept of (USDA); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA); Natl Security Council (NSC); Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Office of the Vice President of the United States; Food & Drug Administration (FDA); Securities & Exchange Commission (SEC)

Bills named: H.R. 2179 (114th), H.R. 3539 (114th), S. 341 (114th), S. 1267 (114th), H.R. 880 (114th), H.R. 2029 (114th), H.R. 3084 (114th), S. 537 (114th)

Copyright/Patent/Trademark CPT

Patent Reform ---S.1137: The PATENTS Act of 2015 ---H.R. 9: Innovation Act ---Implementation of the America Invents Act of 2011 ---H.R.2029: Consolidated Appropriations Act for FY 2016 Bayh-Dole Act/Tech Transfer ---Commercialization of Federally Funded Research Initiative Intellectual Property International Enforcement Transpacific Partnership ---Data and Intellectual Property Protections for Pharmaceuticals Transatlantic Trade and Investment Partnership ---Intellectual Property Issues Drug Patent Settlements ---S.1137: The PATENTS Act of 2015 ---S. 2019: Preserve Access to Affordable Generics Act of 2015 Inter Partes Review ---Implementation of the American Invents Act of 2011 ---S.1137: The PATENTS Act of 2015 ---H.R. 9: Innovation Act ---H.R.2029: Consolidated Appropriations Act for FY 2016

Contacted: Office of the Vice President of the United States; U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Natl Security Council (NSC); Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Securities & Exchange Commission (SEC); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); SENATE; Food & Drug Administration (FDA); Congressional Budget Office (CBO); Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO)

Bills named: H.R. 9 (114th), H.R. 2029 (114th), S. 1137 (114th), S. 2019 (114th)

Health Issues HCR

Biosimilars ---Biosimilar User Fee Act Implementation ---Coding ---Colombia Biologics Regulations ---Implementation of Affordable Care Act ---Interchangeability and Pharmacy Substitution ---Mexico Biologics Regulations ---Naming Funding for the National Institutes of Health ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Centers for Disease Control and Prevention Vaccine Programs ---H.R.2029: Consolidated Appropriations Act for FY 2016 Vaccine Access/Financing ---Vaccine Injury Compensation Program 340B Drug Pricing Program ---Program Implementation & Oversight ---H.R.2029: Consolidated Appropriations Act for FY 2016 Medicaid Pricing and Rebates ---Implementation of Affordable Care Act ---Average Manufacturer Price Calculations Drug Importation ---H.R.2029: Consolidated Appropriations Act for FY 2016 ---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015 Diagnostics and Personalized Medicine Regulation and Oversight Funding for FDA ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.R.2029: Consolidated Appropriations Act for FY 2016 Biodefense Research, Development, and Procurement Issues TransPacific Partnership ---Data and Intellectual Property Protections for Pharmaceuticals Transatlantic Trade and Investment Partnership ---Intellectual Property Issues ---Reimbursement Transparency Reimbursement for Innovative Products ---Medicare Part B Physician-Administered Products ---Medicare Part D Prescription Drug Program ---Value-based contracting and communications Drug Evaluation and Review ---Compassionate Use/Expanded Access ---FDA Proposed Rule on Changes to Drug Labeling ---Implementation of the FDA Safety and Innovation Act ---Reauthorization of the Prescription Drug User Fee Act ---Special Medical Use/Limited Population Drug Orphan Drug Act Tax Credit Senate Innovation for Healthier Americans ---Biomarkers and Regulatory Science Improvements ---Communication with Healthcare Professionals and Payors ---Expanded Access to Investigational Drugs ---Expedited Pathways ---FDA Hiring Flexibility ---FDA Management and Financial Accountability ---Innovation Incentives ---Longitudinal Study of Chronic Diseases ---Patient Access to Approved Drugs ---Patient-Focused Drug Development ---Use of Real-World Evidence ---Vaccine and Anti-Microbial Resistance Product Development and Incentives ---Generic Entry Incentives Vaccines and Infectious Diseases - General Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative ---H.R.2029: Consolidated Appropriations Act for FY 2016 Government Price Reporting ---H.R.2029: Consolidated Appropriations Act for FY 2016 Gene Editing Technologies ---H.R. 2029: Consolidated Appropriations Act for 2016 Antibiotic & Diagnostic Tax Credit ---H.R. 3539: Antibiotic & Diagnostic Innovation Act Precision Medicine Initiative

Contacted: Office of the Vice President of the United States; Agriculture, Dept of (USDA); Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); Environmental Protection Agency (EPA); SENATE; Natl Security Council (NSC); Securities & Exchange Commission (SEC); Patent & Trademark Office (PTO); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Natl Institutes of Health (NIH)

Bills named: H.R. 2029 (114th), H.R. 3539 (114th)

Small Business SMB

Sarbanes Oxley Section 404 (b) ---H.R. 4139: the Fostering Innovation Act Capital Formation Investment Incentives ---Reform of Capital Gains Rules ---Reform of Net Operating Loss Rules ---Reform of Passive Loss Rules ---S. 341: Start-up Jobs and Innovation Act ---S. 537: COMPETE Act ---H.R. 2179: PARTNER Act Reform of SEC Regulation D ---S. 978: the HALOS Act Expansion of Exemption under SEC Regulation A ---H.R. 1839: Reforming Access for Investments in Startup Enterprises (RAISE) Act Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions XBRL Exemption for Small Public Companies ---H.R. 5405: Promoting Job Creation and Reducing Small Business Burdens Act ---H.R. 1965: Small Company Disclosure Simplification Act Capital Market Enhancements ---H.R. 1525: Disclosure Modernization and Simplification Act ---H.R. 1723: Small Company Simple Registration Act ---H.R. 2064: Improving Access to Capital for Emerging Growth Companies Act ---H.R. 4168: Small Business Capital Formation Enhancement Act ---H.R. 3784: Securities & Exchange Commission Small Business Advocate Act -- H.R. 2357: Accelerating Access to Capital Act Proxy Advisory Services ---Impact of Policies on Small Public Companies

LobbyistCovered position, as disclosed
CHARLES CRAIN —
TOM DILENGE —
ELIZABETH CARTIER ESHAM —
CHARLES H FRITTS —
JEANNE HAGGERTY —
SHELLY MUI-LIPNIK —

Contacted: U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); Health Resources & Services Administration (HRSA); Office of the Vice President of the United States; Environmental Protection Agency (EPA); Office of Science & Technology Policy (OSTP); Congressional Budget Office (CBO); Natl Security Council (NSC); Office of Management & Budget (OMB); Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 4139 (114th), H.R. 1965 (114th), S. 537 (114th), S. 341 (114th), H.R. 2179 (114th), H.R. 5405 (114th), H.R. 4168 (114th), H.R. 2064 (114th), H.R. 3784 (114th), H.R. 1839 (114th), H.R. 1525 (114th), H.R. 2357 (114th), S. 978 (114th), H.R. 1723 (114th)

Medicare/Medicaid MMM

Medicaid Pricing and Rebates ---Implementation of Affordable Care Act ---Average Manufacturer Price Calculations Reimbursement for Innovative Products ---Medicare Part B Physician-Administered Products ---Medicare Part D Prescription Drug Program ---Value-Based Contracting and Communications Senate Innovation for Healthier Americans Initiative ---Patient Access to Approved Drugs Government Price Reporting ---H.R.2029: Consolidated Appropriations Act for FY 2016

Contacted: Natl Institutes of Health (NIH); Agriculture, Dept of (USDA); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Securities & Exchange Commission (SEC); SENATE; Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Office of the Vice President of the United States; Office of Management & Budget (OMB); Patent & Trademark Office (PTO); Office of Science & Technology Policy (OSTP); Natl Security Council (NSC); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA)

Bills named: H.R. 2029 (114th)

Medical/Disease Research/Clinical Labs MED

Funding for National Institutes of Health ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.R.2029: Consolidated Appropriations Act for FY 2016 Biodefense Research, Development, and Procurement Issues (Non-funding) Senate Innovation for Healthier Americans Initiative ---Longitudinal Study of Chronic Diseases Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative ---H.R.2029: Consolidated Appropriations Act for FY 2016 Gene Editing Technologies ---H.R. 2029: Consolidated Appropriations Act for 2016 Precision Medicine Initiative

Contacted: Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Agriculture, Dept of (USDA); HOUSE OF REPRESENTATIVES; Natl Security Council (NSC); Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Congressional Budget Office (CBO); SENATE; Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); Office of Science & Technology Policy (OSTP); Securities & Exchange Commission (SEC); Office of the Vice President of the United States; Natl Institutes of Health (NIH)

Bills named: H.R. 2029 (114th)

Budget/Appropriations BUD

Funding for the USDA ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for FDA ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Centers for Disease Control and Prevention Vaccine Programs ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for the National Institutes of Health ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biomass Crop Assistance Program ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Renewable Chemicals/Bio-based Products ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biofuels ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biorefineries ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative ---H.R.2029: Consolidated Appropriations Act for FY 2016

Contacted: Natl Security Council (NSC); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Environmental Protection Agency (EPA); Patent & Trademark Office (PTO); Securities & Exchange Commission (SEC); Agriculture, Dept of (USDA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Congressional Budget Office (CBO); Office of the Vice President of the United States; U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); Office of Science & Technology Policy (OSTP)

Bills named: H.R. 2029 (114th)

Consumer Issues/Safety/Products CSP

Livestock Cloning/Product Labeling ---Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals ---FDA Approval ---Labeling ---One Health Legislation (Senate Discussion Draft) ---H.R.2029: Consolidated Appropriations Act for FY 2016 -------Amendment to Restrict FDA Approval of GE Salmon -------Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology ---U.S. Government Policy ---H.R. 1599: Safe and Accurate Food Labeling Act of 2015 ---H.R.2029: Consolidated Appropriations Act for FY 2016 Biosimilars ---Colombia Biologics Regulations ---Mexico Biologics Regulations ---Implementation of Affordable Care Act ---Interchangeability and Pharmacy Substitution ---Naming USDA/APHIS Agricultural Biotechnology Regulations ---Efficient Science-Based Review of Biotech Products ---Co-existence of Production Systems Drug Importation ---H.R.2029: Consolidated Appropriations Act for FY 2016 ---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015

Contacted: Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Office of the Vice President of the United States; U.S. Trade Representative (USTR); SENATE; Natl Institutes of Health (NIH); Natl Security Council (NSC); Agriculture, Dept of (USDA); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Congressional Budget Office (CBO); Securities & Exchange Commission (SEC); Environmental Protection Agency (EPA)

Bills named: H.R. 2029 (114th), H.R. 1599 (114th)

Energy/Nuclear ENG

Biofuels (Non-Funding) ---Accelerated Depreciation Extension ---Climate Change Benefits ---Production Tax Credit Extension ---Implementation of the Agricultural Act of 2014 ---H.R. 2029: Consolidated Appropriations Act of FY 2016 -------Protecting Americans from Tax Hikes (PATH) Act of 2015 Renewable Chemicals/Bio-based Products (Non-Funding) ---Nomenclature Usage ---Pre-market Notification Review ---S. 697: Chemical Safety for the 21st Century Act ---H.R. 2576: TSCA Modernization Act ---S. 1447: Sustainable Chemistry Research and Development Act ---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act Funding for Biomass Crop Assistance Program ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Renewable Chemicals/Bio-based Products ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biofuels ---H.R.2029: Consolidated Appropriations Act for FY 2016 Funding for Biorefineries --H.R.2029: Consolidated Appropriations Act for FY 2016 EPA Regulation of Biotechnology ---EPA Points to Consider Guidance Document for GE Algae Renewable Fuel Standard ---Proposed Rule Review of the Federal Coordinated Framework for Biotechnology Products

LobbyistCovered position, as disclosed
TOM DILENGE —
CHARLES H FRITTS —
JEANNE HAGGERTY —
TRACEY LATURNER —
ERICK LUTT —
DANA MAURICE O'BRIEN —
RINA SINGH —

Contacted: Agriculture, Dept of (USDA); Office of the Vice President of the United States; Office of Science & Technology Policy (OSTP); Securities & Exchange Commission (SEC); Food & Drug Administration (FDA); Natl Security Council (NSC); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); Patent & Trademark Office (PTO); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Natl Institutes of Health (NIH)

Bills named: H.R. 2576 (114th), S. 697 (114th), H.R. 3084 (114th), H.R. 2029 (114th), S. 1267 (114th), S. 1447 (114th)

Food Industry (safety, labeling, etc.) FOO

Livestock Cloning/Product Labeling ---Discussions with EU on Animal Cloning Genetically Engineered (GE) Animals ---FDA Approval ---Labeling ---One Health Legislation ---H.R.2029: Consolidated Appropriations Act for FY 2016 ------Amendment to Restrict FDA Approval of GE Salmon ------Amendment on GE Salmon Labeling Review and Labeling of Food Derived From Biotechnology ---U.S. Government Policy ---H.R. 1599: Safe and Accurate Food Labeling Act of 2015 ---H.R.2029: Consolidated Appropriations Act for FY 2016

LobbyistCovered position, as disclosed
BRIAN T BAENIG —
TOM DILENGE —
JEANNE HAGGERTY —
TRACEY LATURNER —
DANA MAURICE O'BRIEN —
MATTHEW O'MARA —

Contacted: Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Natl Security Council (NSC); Office of Science & Technology Policy (OSTP); Health Resources & Services Administration (HRSA); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Agriculture, Dept of (USDA); Congressional Budget Office (CBO); Securities & Exchange Commission (SEC); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States; SENATE

Bills named: H.R. 1599 (114th), H.R. 2029 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.